Natco Pharma, Alembic Win Legal Battle Against Bayer; Allowed To Export Select Drugs For R&D
In what comes as a relief to Natco Pharma Ltd. and Alembic Pharmaceuticals Ltd. engaged in a legal battle with Germany's Bayer AG, the Delhi High Court on Wednesday allowed both drugmakers to export select active pharmaceutical ingredients (APIs) for research and development (R&D) purposes.
The court had barred Natco from exporting kidney cancer drug Sorafenat API in 2014. Sorafenat is manufactured by the Indian company under compulsory licence for Bayer's patented drug Nexavar.
Bayer had argued that compulsory licence is only for sale of the drug in India and Natco should not be allowed to export the drug's API. Natco sought to export samples of the drug's API to generate clinical trial data for submitting to regulators of various countries.
The court also allowed Alembic Pharmaceuticals Ltd. to export Rivaroxaban API for R&D. Bayer has patent over Rivaroxaban, a blood thinner, and sought a restraining order on Alembic from exporting the drug for R&D and/or regulatory use overseas.
“The court has re-iterated that pharma industry growth cannot be stunted in this manner. This judgement will dissuade frivolous litigation for or against Indian generic makers,” said senior advocate Pratibha Singh, who represented Alembic.
Rejecting Bayer's plea that only data should be exported, the court said exporting products is a constitutional right of Indian companies, Singh told reporters after the hearing. The judgment was passed by Justice RS Endlaw.
The Natco Pharma stock rose as much as 3.17 percent to Rs 792, while Alembic Pharmaceuticals stock jumped as much as 5.98 percent to Rs 623.5 after the court's verdict.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
